257 related articles for article (PubMed ID: 26075823)
1. Death-associated protein kinase 1 promotes growth of p53-mutant cancers.
Zhao J; Zhao D; Poage GM; Mazumdar A; Zhang Y; Hill JL; Hartman ZC; Savage MI; Mills GB; Brown PH
J Clin Invest; 2015 Jul; 125(7):2707-20. PubMed ID: 26075823
[TBL] [Abstract][Full Text] [Related]
2. Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers.
Rodriguez-Acebes S; Proctor I; Loddo M; Wollenschlaeger A; Rashid M; Falzon M; Prevost AT; Sainsbury R; Stoeber K; Williams GH
Am J Pathol; 2010 Oct; 177(4):2034-45. PubMed ID: 20724597
[TBL] [Abstract][Full Text] [Related]
3. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.
Yanai A; Inoue N; Yagi T; Nishimukai A; Miyagawa Y; Murase K; Imamura M; Enomoto Y; Takatsuka Y; Watanabe T; Hirota S; Sasa M; Katagiri T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):197-203. PubMed ID: 25600244
[TBL] [Abstract][Full Text] [Related]
4. Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells.
Liang Y; Besch-Williford C; Benakanakere I; Hyder SM
Int J Oncol; 2007 Oct; 31(4):777-84. PubMed ID: 17786308
[TBL] [Abstract][Full Text] [Related]
5. Mutant p53 Amplifies Epidermal Growth Factor Receptor Family Signaling to Promote Mammary Tumorigenesis.
Yallowitz AR; Li D; Lobko A; Mott D; Nemajerova A; Marchenko N
Mol Cancer Res; 2015 Apr; 13(4):743-54. PubMed ID: 25573952
[TBL] [Abstract][Full Text] [Related]
6. Gliotoxin Enhances Autophagic Cell Death via the DAPK1-TAp63 Signaling Pathway in Paclitaxel-Resistant Ovarian Cancer Cells.
Park GB; Jeong JY; Kim D
Mar Drugs; 2019 Jul; 17(7):. PubMed ID: 31336860
[TBL] [Abstract][Full Text] [Related]
7. Tumor-suppressive effect of adenovirus-mediated inhibitor of growth 4 gene transfer in breast carcinoma cells in vitro and in vivo.
Li Z; Xie Y; Sheng W; Miao J; Xiang J; Yang J
Cancer Biother Radiopharm; 2010 Aug; 25(4):427-37. PubMed ID: 20707719
[TBL] [Abstract][Full Text] [Related]
8. Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer.
Gallenne T; Ross KN; Visser NL; Salony ; Desmet CJ; Wittner BS; Wessels LFA; Ramaswamy S; Peeper DS
Oncotarget; 2017 Mar; 8(13):20572-20587. PubMed ID: 28411283
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells.
Chen L; Mayer JA; Krisko TI; Speers CW; Wang T; Hilsenbeck SG; Brown PH
Cancer Res; 2009 Dec; 69(23):8853-61. PubMed ID: 19920204
[TBL] [Abstract][Full Text] [Related]
10. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
11. Pancreas-specific activation of mTOR and loss of p53 induce tumors reminiscent of acinar cell carcinoma.
Kong B; Cheng T; Qian C; Wu W; Steiger K; Cao J; Schlitter AM; Regel I; Raulefs S; Friess H; Erkan M; Esposito I; Kleeff J; Michalski CW
Mol Cancer; 2015 Dec; 14():212. PubMed ID: 26683340
[TBL] [Abstract][Full Text] [Related]
12. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
Shapira I; Lee A; Vora R; Budman DR
Crit Rev Oncol Hematol; 2013 Nov; 88(2):284-92. PubMed ID: 23755891
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
14. SRC Increases
Abdullah C; Korkaya H; Iizuka S; Courtneidge SA
Mol Cell Biol; 2018 Mar; 38(6):. PubMed ID: 29263157
[TBL] [Abstract][Full Text] [Related]
15. Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
Bessette DC; Tilch E; Seidens T; Quinn MC; Wiegmans AP; Shi W; Cocciardi S; McCart-Reed A; Saunus JM; Simpson PT; Grimmond SM; Lakhani SR; Khanna KK; Waddell N; Al-Ejeh F; Chenevix-Trench G
PLoS One; 2015; 10(5):e0125232. PubMed ID: 25969993
[TBL] [Abstract][Full Text] [Related]
16. Targeting triple negative breast cancer: is p53 the answer?
Turner N; Moretti E; Siclari O; Migliaccio I; Santarpia L; D'Incalci M; Piccolo S; Veronesi A; Zambelli A; Del Sal G; Di Leo A
Cancer Treat Rev; 2013 Aug; 39(5):541-50. PubMed ID: 23321033
[TBL] [Abstract][Full Text] [Related]
17. 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.
Yang H; Shu Z; Jiang Y; Mao W; Pang L; Redwood A; Jeter-Jones SL; Jennings NB; Ornelas A; Zhou J; Rodriguez-Aguayo C; Bartholomeusz G; Iles LR; Zacharias NM; Millward SW; Lopez-Berestein G; Le XF; Ahmed AA; Piwnica-Worms H; Sood AK; Bast RC; Lu Z
Clin Cancer Res; 2019 Sep; 25(18):5702-5716. PubMed ID: 31391192
[TBL] [Abstract][Full Text] [Related]
18. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
19. IGFBP7 reduces breast tumor growth by induction of senescence and apoptosis pathways.
Benatar T; Yang W; Amemiya Y; Evdokimova V; Kahn H; Holloway C; Seth A
Breast Cancer Res Treat; 2012 Jun; 133(2):563-73. PubMed ID: 21997538
[TBL] [Abstract][Full Text] [Related]
20. Grifolin, a potent antitumour natural product upregulates death-associated protein kinase 1 DAPK1 via p53 in nasopharyngeal carcinoma cells.
Luo XJ; Li LL; Deng QP; Yu XF; Yang LF; Luo FJ; Xiao LB; Chen XY; Ye M; Liu JK; Cao Y
Eur J Cancer; 2011 Jan; 47(2):316-25. PubMed ID: 20943371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
